JP2006517109A - アンフィレグリン抗体ならびに癌および乾癬を処置するためのその使用 - Google Patents

アンフィレグリン抗体ならびに癌および乾癬を処置するためのその使用 Download PDF

Info

Publication number
JP2006517109A
JP2006517109A JP2006503535A JP2006503535A JP2006517109A JP 2006517109 A JP2006517109 A JP 2006517109A JP 2006503535 A JP2006503535 A JP 2006503535A JP 2006503535 A JP2006503535 A JP 2006503535A JP 2006517109 A JP2006517109 A JP 2006517109A
Authority
JP
Japan
Prior art keywords
antibody
seq
antibodies
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006503535A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006517109A5 (https=
Inventor
ニコラス エフ． ランドルフィ，
直也 鶴下
ポール アール． ヒントン，
シャンカー クマー，
Original Assignee
プロテイン デザイン ラブス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロテイン デザイン ラブス インコーポレイテッド filed Critical プロテイン デザイン ラブス インコーポレイテッド
Publication of JP2006517109A publication Critical patent/JP2006517109A/ja
Publication of JP2006517109A5 publication Critical patent/JP2006517109A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006503535A 2003-02-07 2004-02-06 アンフィレグリン抗体ならびに癌および乾癬を処置するためのその使用 Pending JP2006517109A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44564003P 2003-02-07 2003-02-07
US53390103P 2003-12-30 2003-12-30
PCT/US2004/004176 WO2004068931A2 (en) 2003-02-07 2004-02-06 Amphiregulin antibodies and their use to treat cancer and psoriasis

Publications (2)

Publication Number Publication Date
JP2006517109A true JP2006517109A (ja) 2006-07-20
JP2006517109A5 JP2006517109A5 (https=) 2007-03-29

Family

ID=32853408

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006503535A Pending JP2006517109A (ja) 2003-02-07 2004-02-06 アンフィレグリン抗体ならびに癌および乾癬を処置するためのその使用

Country Status (5)

Country Link
US (2) US7223393B2 (https=)
EP (1) EP1608684A2 (https=)
JP (1) JP2006517109A (https=)
CA (1) CA2515081A1 (https=)
WO (1) WO2004068931A2 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007135581A (ja) * 2005-10-20 2007-06-07 Japan Science & Technology Agency 自己免疫性血小板減少性紫斑病（ｉｔｐ）患者の血液細胞特異的遺伝子群
JP2009513515A (ja) * 2003-07-04 2009-04-02 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ ストレス誘導性リガンド依存性ｅｇｆｒ活性化の阻害
JP2010505934A (ja) * 2006-10-11 2010-02-25 フージョン アンティボディーズ リミテッド 併用療法
JP2013537424A (ja) * 2010-08-14 2013-10-03 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
JP2023519007A (ja) * 2020-03-27 2023-05-09 ナショナル インスティテュート オブ バイオロジカル サイエンシズ，ベイジン Ａｒｅｇに対する抗体及びその用途

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1449538A1 (en) * 2003-02-21 2004-08-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation
DE102004010050A1 (de) * 2004-03-02 2005-09-22 Bayer Healthcare Ag Spezifische monoklonale und polyklonale Antikörper für Repinotan und dessen ringoffene Form
CA2568427A1 (en) * 2004-05-27 2006-01-12 Tanox, Inc. Method for preventing and treating mast cell mediated diseases
US20060063930A1 (en) * 2004-08-20 2006-03-23 Agoston Gregory E Compositions and methods comprising proteinase activated receptor antagonists
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
CA2633718A1 (en) * 2005-12-21 2007-07-05 Medimmune, Llc Affinity optimized epha2 agonistic antibodies and methods of use thereof
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8519106B2 (en) * 2007-03-13 2013-08-27 University Of Zurich Monoclonal human tumor-specific antibody
JP2010235447A (ja) * 2007-07-30 2010-10-21 Igaku Seibutsugaku Kenkyusho:Kk 炎症性サイトカインの抑制剤
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
AU2008304748C1 (en) 2007-09-26 2014-06-12 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
CA2708532C (en) 2007-12-05 2018-06-05 Chugai Seiyaku Kabushiki Kaisha Anti-il31ra antibody and use thereof
GB0807018D0 (en) 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
TWI682995B (zh) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
KR20120024763A (ko) 2009-05-15 2012-03-14 추가이 세이야쿠 가부시키가이샤 항ａｘｌ 항체
WO2010137012A1 (en) 2009-05-25 2010-12-02 Ramot At Tel-Aviv University Ltd. Peptide therapy for amphiregulin mediated diseases
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
JP5889181B2 (ja) 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
JP5273689B2 (ja) 2010-09-29 2013-08-28 株式会社エヌビィー健康研究所 ヒトプロスタグランジンｅ２受容体ｅｐ４に対する抗体
PH12016502073B1 (en) 2010-11-17 2024-04-05 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
CN112812184A (zh) 2011-02-25 2021-05-18 中外制药株式会社 FcγRIIb特异性Fc抗体
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
US20140302050A1 (en) * 2011-11-09 2014-10-09 Albert Einstein College Of Medicine Of Yeshiva University Targeting an amphiregulin-derived cell surface neo-epitope
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
JP6534615B2 (ja) 2013-09-27 2019-06-26 中外製薬株式会社 ポリペプチド異種多量体の製造方法
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
CN107207607B (zh) 2014-12-19 2021-05-04 中外制药株式会社 抗-c5抗体及使用方法
CN114773470A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
JP6130983B2 (ja) 2015-02-27 2017-05-17 中外製薬株式会社 Ｉｌ−６関連疾患治療用組成物
IL237852A0 (en) * 2015-03-19 2016-03-24 Yeda Res & Dev Antibodies against amphigoline, medical preparations containing them and their use
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN108368166B (zh) 2015-12-28 2023-03-28 中外制药株式会社 提高含fc区多肽纯化效率的方法
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
MA44780A (fr) 2016-04-28 2019-03-06 Chugai Pharmaceutical Co Ltd Préparation contenant un anticorps
IL299099B2 (en) 2016-06-27 2025-07-01 Univ California Cancer treatment combinations
TWI693940B (zh) 2016-08-05 2020-05-21 日商中外製藥股份有限公司 Ｉｌ-８相關疾病之治療用或預防用組成物
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
AU2018361430B2 (en) 2017-11-01 2025-08-14 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2021202798A1 (en) * 2020-04-02 2021-10-07 The United States Of America As Represented By The Secretary Of The Navy Antigen binding proteins to class 5 etec adhesins
US11933781B2 (en) 2020-12-09 2024-03-19 The Regents Of The University Of Colorado Fibrosis model and methods of use thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN118598996B (zh) * 2024-08-08 2024-11-01 康立泰生物医药(青岛)有限公司 一种抗人白介素8抗体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02104596A (ja) * 1988-01-25 1990-04-17 Oncogen アムフイレグリン
JP2000504206A (ja) * 1995-12-22 2000-04-11 イノジェネティックス・ナムローゼ・フェンノートシャップ 新規形態のアンフィレグリン、その製造方法および使用方法、ならびにそれを含む組成物
WO2001045697A1 (en) * 1999-12-21 2001-06-28 Kanebo, Limited Skin external agents and drugs

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668629A (en) * 1980-07-18 1987-05-26 The Board Of Trustees Of Leland Stanford Jr. University Human hybridomas, precursors and products
US5115096A (en) 1988-04-15 1992-05-19 Oncogen Amphiregulin: a bifunctional growth modulating glycoprotein
US5262298A (en) 1989-05-12 1993-11-16 The State Of Oregon Acting By And Through The State Board Of Education On Behalf Of The Oregon Health Sciences University Method to assess the ability of a substance to inhibit or stimulate keratinocyte autocrine factor production
WO1990014069A2 (en) 1989-05-12 1990-11-29 The State Of Oregon Acting By And Through The State Board Of Education On Behalf Of The Oregon Health Sciences University Keratinocyte autocrine factor
US5855885A (en) 1993-01-22 1999-01-05 Smith; Rodger Isolation and production of catalytic antibodies using phage technology
JPH10507362A (ja) 1994-10-14 1998-07-21 ブリストル−マイヤーズ スクイブ カンパニー Ｈｅｒ４ヒトレセプタチロシンキナーゼ
EP1053319A2 (en) 1998-01-28 2000-11-22 Chiron Corporation Human genes and gene expression products ii
US6677436B1 (en) * 1998-04-03 2004-01-13 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody
EP1074617A3 (en) 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
EP1263960A2 (en) * 2000-03-16 2002-12-11 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
US20030165831A1 (en) 2000-03-21 2003-09-04 John Lee Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
AU2001266790A1 (en) 2000-06-09 2001-12-24 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
AU2002210791A1 (en) 2000-07-28 2002-02-13 Compugen Inc. Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome
US20020156263A1 (en) 2000-10-05 2002-10-24 Huei-Mei Chen Genes expressed in breast cancer
AU2002239717A1 (en) 2000-10-20 2002-06-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
CA2426540A1 (en) 2000-10-20 2002-07-25 Biocardia, Inc. Leukocyte expression profiling
WO2002077234A2 (en) 2000-10-31 2002-10-03 Diadexus, Inc. Compositions and methods relating to colon specific genes and proteins
US20030087855A1 (en) 2001-09-13 2003-05-08 Isis Pharmaceuticals Inc. Antisense modulation of protein kinase R expression
WO2003008583A2 (en) 2001-03-02 2003-01-30 Sagres Discovery Novel compositions and methods for cancer
JP2004519247A (ja) 2001-03-20 2004-07-02 オーソ・クリニカル・ダイアグノスティックス・インコーポレーテッド 発現プロファイルおよび使用法
AU2002307466A1 (en) 2001-04-20 2002-11-05 Millennium Pharmaceutical, Inc. Method for detecting breast cancer cells
JP2004537289A (ja) 2001-05-11 2004-12-16 ゲノム　セラピューティックス　コーポレーション 骨量および脂質レベルを調整するｈｂｍ変異型
JP2005508887A (ja) 2001-08-03 2005-04-07 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション Ｅｇｆ受容体の結晶構造に基づいたスクリーニング方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02104596A (ja) * 1988-01-25 1990-04-17 Oncogen アムフイレグリン
JP2000504206A (ja) * 1995-12-22 2000-04-11 イノジェネティックス・ナムローゼ・フェンノートシャップ 新規形態のアンフィレグリン、その製造方法および使用方法、ならびにそれを含む組成物
WO2001045697A1 (en) * 1999-12-21 2001-06-28 Kanebo, Limited Skin external agents and drugs

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009513515A (ja) * 2003-07-04 2009-04-02 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ ストレス誘導性リガンド依存性ｅｇｆｒ活性化の阻害
JP2011084580A (ja) * 2003-07-04 2011-04-28 Max-Planck-Ges Zur Foerderung Der Wissenschaften Ev ストレス誘導性リガンド依存性ｅｇｆｒ活性化の阻害
JP2007135581A (ja) * 2005-10-20 2007-06-07 Japan Science & Technology Agency 自己免疫性血小板減少性紫斑病（ｉｔｐ）患者の血液細胞特異的遺伝子群
JP2010505934A (ja) * 2006-10-11 2010-02-25 フージョン アンティボディーズ リミテッド 併用療法
JP2013537424A (ja) * 2010-08-14 2013-10-03 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
JP2017048194A (ja) * 2010-08-14 2017-03-09 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
JP2023519007A (ja) * 2020-03-27 2023-05-09 ナショナル インスティテュート オブ バイオロジカル サイエンシズ，ベイジン Ａｒｅｇに対する抗体及びその用途
JP7564882B2 (ja) 2020-03-27 2024-10-09 ナショナル インスティテュート オブ バイオロジカル サイエンシズ，ベイジン Ａｒｅｇに対する抗体及びその用途

Also Published As

Publication number Publication date
WO2004068931A2 (en) 2004-08-19
WO2004068931A3 (en) 2005-03-24
US20040210040A1 (en) 2004-10-21
EP1608684A2 (en) 2005-12-28
US7223393B2 (en) 2007-05-29
CA2515081A1 (en) 2004-08-19
US20080226632A1 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
US7223393B2 (en) Amphiregulin antibodies and their use to treat cancer and psoriasis
JP2006517109A5 (https=)
US9855291B2 (en) Anti-kidney associated antigen 1 (KAAG1) antibodies
JP2021120382A (ja) 部位特異的抗体コンジュゲーション方法および組成物
JP7003036B2 (ja) グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法
KR102618312B1 (ko) 항muc16 항체 및 그의 용도
CN121873244A (zh) 对nectin-4具有特异性的抗体及其用途
JP2019516705A (ja) 神経内分泌移行のリスクのある腫瘍を治療するための抗ｄｌｌ３薬物コンジュゲート
JP2016538318A (ja) 新規ｓｅｚ６モジュレーターおよび使用方法
US20080260740A1 (en) Anti-LFL2 Antibodies for the Diagnosis, Prognosis and Treatment of Cancer
AU2016316758B2 (en) Antibodies and assays for detection of CD37
JP2021503915A (ja) ヒト組織因子を標的とするヒト化抗体
WO2011054112A1 (en) Antibodies that specifically block the biological activity of kidney associated antigen 1
US12043671B2 (en) Antibodies targeting an amphiregulin-derived cell surface neo-epitope
JPWO2012124334A1 (ja) 抗体、乳がんの治療に用いられる医薬組成物、腫瘍検査方法、及び、腫瘍検査用試薬
HK1234432A (en) Antibodies that specifically block the biological activity of a tumor antigen
HK1234432A1 (en) Antibodies that specifically block the biological activity of a tumor antigen
HK1234432B (en) Antibodies that specifically block the biological activity of a tumor antigen
NZ626513B2 (en) Anti-cd98 antibodies and methods of use thereof

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20070205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100112

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100617